Zydus Lifesciences receives final approval from USFDA for Famotidine Tablets

Zydus Lifesciences Ltd. (formerly known as Cadila Healthcare Ltd.), has received final approval from the United States Food and Drug Administration (USFDA) to market Famotidine Tablets in the strengths of 20mg and 40mg (USRLD: Pepcid). Famotidine is a histamine H2 receptor blocker. It works by reducing the amount of acid in the stomach. It is used to prevent and treat heartburn and other symptoms caused by excessive acid in the stomach (acid indigestion). The drug will be manufactured at group's drug formulation facility at SEZ, Ahmedabad. Famotidine Tablet has a market size of USD 67 mn (as per IQVIA MAT April 2022).

The group now has 315 approvals and has so far filed over 420* ANDAs since the commencement of the filing process in FY 2003-04.

Shares of Cadila Healthcare Limited was last trading in BSE at Rs. 362.95 as compared to the previous close of Rs. 364.95. The total number of shares traded during the day was 27439 in over 798 trades.

The stock hit an intraday high of Rs. 368.70 and intraday low of 362.40. The net turnover during the day was Rs. 10024722.00.

Source : Equity Bulls

Keywords

ZydusLifesciences CadilaHealthcare INE010B01027 USFDA FinalApproval FamotidineTabelts Pepcid